Welcome to KeyBioscience

Pioneering Metabolic Peptide Solutions

About us

KeyBioscience is strongly committed to the discovery of novel peptide therapeutics for metabolic disorders. Building an extensive peptide profiling platform allows detailed investigation of molecules which are inspired by the evolution of naturally occurring peptide variants.

Utilizing this platform we have identified 3 peptides which have entered clinical development for Type 2 Diabetes, obesity and osteoarthritis. Two of these were licensed to Eli Lilly in 2017, and of these a second generation of the Lilly-KeyBio DACRAs is now in clinical development for Obesity. At KeyBioscience we are now focusing on the newest member of the KBP family, namely the long-acting KBP-336, which is under development as a once weekly injectable for metabolic osteoarthritis.

Our technology

The DACRA Project

KeyBioscience’s peptide platform focuses on discovering novel therapeutics for metabolic disorders, leveraging an extensive profiling platform inspired by naturally occurring peptide variants. Utilizing innovative screening systems, KeyBioscience engineers DACRAs with prolonged receptor activation, aiming for once-weekly dosing, exemplified by KBP-336’s superior potency, stability, and efficacy, marking a significant advancement in metabolic therapy.

Contact us

How can we
help you?

Are you interested in learning more about KeyBioscience?